Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

No evidence of carcinogenicity in NexACT rat study

June 2, 2003

Phase II efficacy data reported for intranasal apomorphine in FSD

June 2, 2003

Oxytrol submission accepted for review in Canada

May 28, 2003

Solifenacin succinate safe and effective in patients with overactive bladder

May 26, 2003

Favorable effects on bone disease reported for lanthanum carbonate in hemodialysis

May 23, 2003

New data on vardenafil reported at the American Geriatrics Society meeting

May 20, 2003

17Beta-HSD-3 inhibitors in early development at Schering-Plough

May 19, 2003

Phase IIa trial evaluates VR-004 delivered via lungs for ED

May 15, 2003

At-home phase IIb study begins for ED treatment PT-141

May 15, 2003

Novartis acquires Enablex

May 13, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...